Skip to main content

Table 3 Percentage of low risk of bias studies per treatment arm in the meta-analysis on exacerbation rate [13, 15, 19, 33,34,35,36,37,38,39,40,41,42]

From: Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis

Treatment Percentage
Benralizumab 60% (3/5)
Lebrikizumab 50% (1/2)
Dupilumab 0% (0/1)
Mepolizumab 50% (1/2)
Tralokinumab 100% (1/1)
Reslizumab 100% (1/1)
Tezepelumab 100% (1/1)
  1. Table outlining the risk of bias for different studies included in the meta-analysis, all agents had at least 50% of low-risk studies included, except dupilumab